Key Day 100 Survival Results In P3 GvHD Trial
Filed with ASX · · 2 pages · English
In the deck
Story so far
Earlier from Mesoblast
- Partnership For Allogeneic Cell-based Cancer Immunotherapies
- MSB Enters Into $75 Million Non-Dilutive Credit Facility
- GVHD Day 28 Results Presentation
- Primary Endpoint Successfully Achieved in MSB P3 GVHD Trial
- Appendix 3B with prospectus
Later from Mesoblast
- MSB Enters Into US$50M Financing With NovaQuest Capital
- MSB Enters Into Cardiovascular Alliance For China With Tasly
- Update on Tasly transaction
- Mesoblast Reports on Annual and Fourth Quarter Results
- Tasly Receives Approvals For Transaction With MSB
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast